CAR-T Cell Therapy i Apollo Hospitals, Lucknow

Why Patients Choose Apollo Hospitals for CAR-T Cell Therapy

• Legacy of over 40 years: The Apollo Hospitals Group began in 1983 in Chennai and today operates one of Asia's largest integrated healthcare networks, with more than 70 hospitals and a group-wide experience of treating patients from over 120 countries.
• Apollomedics Super Speciality Hospital, Lucknow: A multi-super-speciality tertiary facility in Uttar Pradesh with dedicated departments for Medical Oncology, Haemato-Oncology, Bone Marrow Transplant, Radiation Oncology and Surgical Oncology working as one tumour board.
• Multidisciplinary CAR-T team: Haemato-oncologists, transplant physicians, transfusion medicine and apheresis specialists, intensivists, neurologists, infectious disease consultants, clinical pharmacologists, transplant nurses and dietitians. The exact number of consultants attached to the CAR-T programme and their individual years of experience are shared by the oncology coordinator when you book, since the panel changes over time.
• Apheresis and cell-processing capability: Leukapheresis for T-cell collection, cryopreservation-ready handling, and coordination with licensed CAR-T manufacturing partners in India.
• HEPA-filtered BMT and isolation beds plus a critical care unit experienced in managing cytokine release syndrome (CRS) and ICANS (immune effector cell-associated neurotoxicity syndrome), with tocilizumab and steroid protocols and 24x7 intensivist cover.
• Diagnostic depth under one roof: Flow cytometry, immunophenotyping, cytogenetics, molecular and MRD testing, PET-CT, 24x7 blood bank with irradiated and leucodepleted components.
• Programmes tailored by age group: Paediatric and adolescent haemato-oncology pathways for B-cell ALL, separate adult lymphoma and myeloma pathways, and a geriatric assessment approach for older patients with comorbidities.
• India-made CAR-T access: Indian CDSCO-approved products such as NexCAR19 (actalycabtagene autoleucel, approved October 2023) and Qartemi (approved 2025) have brought this therapy within reach of Indian families; eligibility and product availability are confirmed case by case.
• Lagolago atoa-taamilosaga: Insurance and TPA desk, out-of-town patient assistance, counselling, nutrition and long-term survivorship follow-up.

lagona

At Apollo Hospitals Lucknow, we pride ourselves on being at the forefront of medical innovation and patient care. Our CAR-T Cell Therapy program exemplifies our commitment to excellence, utilizing cutting-edge technology to treat complex hematological malignancies. CAR-T Cell Therapy, or Chimeric Antigen Receptor T-cell Therapy, is a revolutionary treatment that harnesses the power of the patient's immune system to fight cancer. With a team of highly skilled oncologists and state-of-the-art facilities, Apollo Hospitals Lucknow is recognized as one of the leading centres for CAR-T Cell Therapy in the region, earning the trust of patients and their families.

Aisea e mana'omia ai le CAR-T Cell Therapy

CAR-T Cell Therapy is a groundbreaking treatment option for patients with certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. Traditional treatments, such as chemotherapy and radiation, may not be effective for all patients, especially those with relapsed or refractory disease. CAR-T Cell Therapy offers a personalized approach, where T-cells are extracted from the patient's blood, genetically modified to target cancer cells, and then reinfused into the patient. This innovative therapy can improve the chance of remission and provides an option for patients who have exhausted other treatment lines.

The medical importance of CAR-T Cell Therapy lies in its ability to specifically target and destroy cancer cells expressing a chosen antigen, such as CD19 or BCMA, rather than dividing cells in general. This precision medicine approach has changed the outlook in relapsed and refractory disease, making it a necessary option to consider for eligible patients. It is not, however, free of risk, and the side-effect profile is different from that of chemotherapy rather than simply milder.

Tulaga lamatia o le tuai

O le tuai o le CAR-T Cell Therapy e mafai ona i ai ni a'afiaga ogaoga mo tagata mama'i o lo'o tauivi ma le kanesa toto. A'o fa'agasolo le fa'ama'i, e mafai ona fa'ateleina ma sosolo atu sela o le kanesa, ma fa'afaigata ai togafitiga ma fa'aitiitia ai le avanoa e maua ai se taunu'uga manuia. O le tolopoina o togafitiga e mafai ona oo atu ai i faʻalavelave e pei o le faʻaleagaina o totoga, faʻateleina le mamafa o le tuma, ma faʻaitiitia le soifua maloloina atoa, lea e mafai ona matua aʻafia ai le aoga o togafitiga mulimuli ane.

There is a second, practical reason not to delay. Manufacturing a CAR-T product takes weeks, and the patient must remain fit enough to receive the cells when they are ready. A patient whose disease accelerates during that window may become ineligible. At Apollo Hospitals Lucknow, our dedicated team works closely with patients to ensure that they receive the necessary evaluations and treatments without unnecessary delays. Early consultation can be pivotal in determining the best course of action for your health.

Fa'amanuiaga ole CAR-T Cell Therapy

• Togafitiga fa'atatau: CAR-T Cell Therapy is designed to specifically target cancer cells carrying a particular marker, sparing many healthy tissues that conventional chemotherapy affects.
• Potential for durable remission: Many patients experience durable responses, and some achieve complete remission that lasts, which can significantly improve quality of life. Responses vary widely and cannot be guaranteed.
• Auala Fa'apitoa: Each treatment is manufactured from the individual patient's own T-cells, so the therapy is unique to that person.
• One-time infusion model: For most patients the modified cells are given as a single infusion, rather than repeated cycles over months.
• Tekinolosi fou: Our advanced facilities, apheresis capability and monitored transplant unit support the highest standard of care throughout the treatment journey.
• Lagolago Atoa: Holistic care including psychological support, nutritional guidance, infection prevention counselling and structured follow-up.

Sauniuniga ma le Toe Fa'aleleia

1. Faatalanoaga: A thorough consultation with our haemato-oncology team to review your medical history, previous treatment lines, biopsy and flow cytometry reports, and treatment options.
2. Pre-treatment Testing: Blood counts, organ function tests, viral serology, PET-CT or bone marrow assessment, cardiac and pulmonary evaluation, and neurological baseline to confirm eligibility.
3. Lagolago Lagolago: Counselling and peer support to help manage anxiety about a long and unfamiliar treatment pathway.
4. Tausiga pe a uma ona togafitia: Close follow-up appointments, monitoring for CRS, neurotoxicity, low counts and infection, and a graded return to normal life.
5. Meaʻai: A balanced, hygienically prepared diet to support recovery. Our dietitians provide individualised plans, including vegetarian and Jain diet options.

Recovery varies from patient to patient. Some experience only mild fever and fatigue; others need intensive monitoring in critical care. Our team at Apollo Hospitals Lucknow provides personalised care and support throughout the recovery journey.

Current Guidelines and Standards Followed

Our CAR-T pathway is built on national and international standards, and is reviewed as those documents are revised:

• Indian Council of Medical Research (ICMR) National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, jointly issued with the Department of Biotechnology, which govern how genetically modified cell products are developed and administered in India.
• Central Drugs Standard Control Organisation (CDSCO) marketing authorisations. NexCAR19 (actalycabtagene autoleucel), developed by ImmunoACT with IIT Bombay and Tata Memorial Centre, received CDSCO approval in October 2023 for relapsed/refractory B-cell lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma in patients aged 15 years and above. An anti-BCMA product, Qartemi, received approval in 2025 for relapsed/refractory multiple myeloma. Availability of any specific product for your case is confirmed by the treating team.
• Indian Society of Hematology and Blood Transfusion (ISHBT) ma le Sosaiete Initia mo le Fa'aliliuina o le Toto ma le Su'u (ISBMT) position statements and registry practice on cellular therapy, infection prophylaxis and transplant-unit standards.
• ASTCT (American Society for Transplantation and Cellular Therapy) consensus grading for CRS and ICANS, 2019, which is the grading system used worldwide and in Indian centres for scoring and treating these toxicities.
• NCCN Clinical Practice Guidelines in Oncology for B-cell lymphomas, ALL and multiple myeloma, and EBMT/JACIE quality principles for cellular therapy units.

What has changed recently: Until 2023, CAR-T therapy for Indian patients meant travelling abroad at a cost most families could not consider. Indigenous, CDSCO-approved CAR-T products manufactured in India have changed that, and the treatment is now delivered at accredited Indian centres. Guidance on outpatient or short-stay monitoring, earlier use of tocilizumab, and use of CAR-T in second-line rather than third-line large B-cell lymphoma has also evolved in recent guideline editions.

Who Is Eligible, and Who Is Not

Commonly considered for CAR-T

• Relapsed or refractory B-cell acute lymphoblastic leukaemia
• Relapsed or refractory diffuse large B-cell lymphoma and some other aggressive B-cell non-Hodgkin lymphomas
• Relapsed or refractory multiple myeloma after prior lines of therapy, where a BCMA-directed product is available
• Adequate heart, lung, liver and kidney function, and a reasonable performance status

Usually not suitable, or needs correction first

• Active uncontrolled infection, including active tuberculosis, which is an important consideration in India
• Active hepatitis B or C or HIV requiring stabilisation before cell collection
• Active central nervous system disease in some protocols
• Severe organ dysfunction, or very poor performance status
• Insufficient T-cells for collection after heavy prior chemotherapy

Eligibility is a team decision made at a tumour board, not a single-doctor decision.

Timing of the Procedure and the Preparation Phase

Timelines are indicative. Manufacturing time, slot availability and your disease behaviour can shorten or lengthen the journey.

Alternatives and Technique Options Compared

Procedures Often Done Alongside CAR-T Therapy

• Central venous catheter or apheresis line insertion for cell collection and infusion
• Mana'o o ga'o ponaivi ma biopsy with MRD testing before and after therapy
• PET-CT or CT for staging and response assessment
• Lumbar puncture with intrathecal chemotherapy where CNS involvement is a concern
• Fertility preservation counselling (semen banking, oocyte or embryo freezing) before lymphodepletion, particularly for younger patients
• Dental and infection screening, including tuberculosis and hepatitis screening
• Echocardiography and pulmonary function testing
• Blood product support with irradiated, leucodepleted components

Toe Fa'aleleia o Vaega i lea Vaega

Returning to Normal Activity, Work and Daily Indian Routines

• Avetaavale: Not permitted for at least 8 weeks after infusion in most protocols, because of the risk of delayed neurological effects. Confirm the date with your consultant.
• Galuega: Desk or work-from-home duties are often possible from around 2 to 3 months. Field jobs, factory floors, farming and travel-heavy roles usually need longer.
• Crowds and gatherings: Weddings, temple queues, melas and crowded public transport are best avoided for the first 3 months.
• Household routines: Floor sleeping is acceptable if the floor is clean and dust-free, but a bed is preferred while counts are low. Squatting and sitting cross-legged are not restricted by the therapy itself, though weakness and giddiness may make rising difficult in the early weeks.
• Indian-style toilets: Use a western commode or a commode chair during the low-count phase, since fainting or unsteadiness in a locked bathroom is a real risk. Keep the door unlatched and someone within earshot.
• faatinoina: Gentle indoor walking from the first weeks; brisk walking and yoga usually from around 6 to 8 weeks; gym, weights and contact sport only after clearance.
• Mea'ai ma vai: Freshly cooked home food, boiled or filtered water, no raw chutneys, salads, cut fruit from vendors, or unpasteurised dairy during the low-immunity period.
• Pets and gardening: Avoid handling soil, cattle, poultry and pet litter for at least 3 months.

Reducing the Risk of Relapse and Complications

• Attend every scheduled review and scan, even when you feel completely well
• Take antiviral, antifungal and anti-pneumocystis prophylaxis exactly as prescribed
• Report fever above 100.4?F (38?C) immediately rather than starting antibiotics at home
• Accept immunoglobulin replacement if recommended for low immunoglobulin levels
• Complete revaccination only on the schedule your team sets, usually starting several months after infusion
• Stop tobacco, gutkha and alcohol completely; both worsen outcomes and infection risk
• Maintain oral and dental hygiene, and treat any dental infection promptly under advice
• Keep diabetes, blood pressure and thyroid disorders well controlled

Considerations for Children, Adolescents and Older Adults

Tamaiti ma talavou

CD19-directed CAR-T has its strongest evidence in paediatric and young adult B-cell ALL. Indian regulatory approval for NexCAR19 currently begins at 15 years of age, so options for younger children are discussed individually and may involve other centres or trials. Children need play-adapted consent, school liaison, growth and endocrine follow-up, and a parent rooming in throughout admission.

Tagata matutua matutua

Age alone does not disqualify a patient. Fitness matters more than the number on the birth certificate. A geriatric assessment covering cardiac reserve, kidney function, cognition, nutrition, falls risk and polypharmacy is done before clearance. Older patients have a somewhat higher risk of neurotoxicity and infection, so monitoring thresholds are lower and discharge is often slower.

If You Choose Not to Have CAR-T Therapy

Declining is a legitimate choice, and it should be an informed one. Depending on your disease, the realistic alternatives are further chemotherapy or targeted therapy, bispecific antibody treatment, a stem cell transplant if you are eligible, a clinical trial, or best supportive care focused on comfort. In relapsed and refractory blood cancers, remissions from further conventional chemotherapy are usually short, and disease progression can bring anaemia, infections, bone pain, bleeding and organ involvement. Our team will explain what to expect either way, will not pressure you, and will continue to provide symptom control and palliative support if you decide against cellular therapy. You may also ask for a second opinion; we will share your records to help you obtain one.

Factors That Influence the Cost of CAR-T Therapy

CAR-T is among the most expensive treatments in oncology, though Indian-manufactured products have brought the cost substantially below international pricing. Apollo Hospitals Lucknow does not publish a fixed package figure, because the total depends on the variables below. Please ask the oncology coordinator or the billing desk for a written estimate for your specific case.

Insurance, Cashless Treatment and Financial Planning in India

• Check coverage in writing first. Many Indian health insurance policies still treat CAR-T and gene therapy as a new or specialised modality; some cover it fully, some cap it, some exclude it. Ask your insurer for a written confirmation before leukapheresis, not after.
• E tāua taimi fa'atali. Standard indemnity policies carry an initial waiting period of about 30 days, and pre-existing disease waiting periods commonly of 2 to 4 years depending on the policy. A cancer diagnosed before the policy started will usually fall under the pre-existing clause.
• Planned versus accident cover. CAR-T is always a planned admission, so accident-only or personal accident policies do not apply. Critical illness riders may pay a lump sum on a confirmed cancer diagnosis, which many families use for the product cost.
• Cashless and TPA process. Submit the pre-authorisation form, doctor's clinical note, diagnosis and estimate through the hospital's insurance desk. Approval for a high-value cellular therapy usually takes longer than for routine surgery, so start early. If cashless is denied, treatment can continue on a reimbursement basis with all original bills and discharge summary retained.
• Sub-limits to check: room rent limit, ICU limit, co-payment percentage, disease-wise capping, and whether consumables and pharmacy are payable.
• Government and employer schemes: CGHS, ECHS, state employee schemes, ESIC and PSU panels have their own approval routes and rate lists; the insurance desk will tell you whether your entitlement applies at this centre.
• Other support: Prime Minister's National Relief Fund, the Health Minister's Cancer Patient Fund, Chief Minister's Relief Fund in Uttar Pradesh, employer welfare funds and recognised charitable trusts. Documentation takes weeks, so apply in parallel with the medical work-up.

Policy-specific approvals, co-payment and package details must be confirmed with the Apollo Hospitals Lucknow insurance and TPA desk at the time of booking.

Planning the Admission and What to Bring

pepa aloaia

• All previous prescriptions, discharge summaries, biopsy and bone marrow reports, flow cytometry and cytogenetics, and prior scan films or CDs
• Aadhaar or photo ID for the patient and the main attendant
• Insurance card, policy document, TPA card and employer or scheme letter
• Blood group card and any prior transfusion records

Aitema a le tagata lava ia

• Loose cotton clothing that opens at the front, and separate clean indoor slippers
• Soft toothbrush, mild soap, personal towel, lip balm
• Phone, long charging cable, headphones; books or a tablet for a two-week stay
• A written list of all current medicines with doses, including ayurvedic or homeopathic preparations, which must be disclosed and usually stopped

Fuafuaga aogā

• Identify one primary attendant plus one backup. In joint families, agree in advance who stays overnight, who manages medicines and who handles billing, so instructions are not lost between relatives.
• Arrange accommodation near the hospital for the four weeks after discharge.
• Plan for someone who can drive at short notice, day or night.
• Do not bring flowers, plants or home-cooked food into the isolation area unless the nursing team permits it.

Warning Signs That Need Immediate Medical Review

Contact the hospital at once, at any hour, if the patient develops:

• Fever of 100.4?F (38?C) or above, or shaking chills
• Confusion, slurred speech, difficulty finding words, tremor, handwriting change or seizure
• Excessive drowsiness or difficulty waking
• Breathlessness, chest pain, fast heartbeat or dizziness on standing
• Fa'aititia le mimi
• Bleeding from gums or nose, blood in urine or stool, or new widespread bruising
• Persistent vomiting, severe diarrhoea or inability to keep fluids down
• Severe headache, neck stiffness or new visual disturbance

Carry your CAR-T patient card at all times and show it to any doctor you consult elsewhere, including at a local clinic.

Mo Gasegase o loʻo Malaga mai Itumalo ma Aai Latalata ane

Apollo Hospitals Lucknow receives patients from across Uttar Pradesh and neighbouring states, including Kanpur, Barabanki, Sitapur, Hardoi, Unnao, Raebareli, Sultanpur, Faizabad and Ayodhya, Gonda, Bahraich, Basti, Gorakhpur, Varanasi, Prayagraj, Jhansi, Bareilly, Moradabad and Meerut, as well as parts of Bihar, Uttarakhand, Madhya Pradesh and Nepal.

• Before you travel: Email or share scanned reports so the team can advise whether a visit is worthwhile and what to bring.
• Cluster your visits: Ask the coordinator to schedule consultation and investigations on consecutive days.
• Do not plan to commute during monitoring. For roughly four weeks after infusion you must stay in Lucknow, within a short drive of the hospital. Budget for accommodation and an attendant's living costs.
• Taunuu iinei: Lucknow is served by Chaudhary Charan Singh International Airport, Lucknow Charbagh and Gomti Nagar railway stations, and good road links along the Agra?Lucknow and Purvanchal Expressways.
• Local medical backup: Identify a hospital with a functioning emergency department near your home town for the period after you return, and keep your discharge summary and the CAR-T card with you.
• Nepal and other international patients: Contact the international patient desk in advance for visa documentation, currency and interpreter support.

Feso'ota'iga ma Taimi Fa'atulagaina

Fesili e Masani ona Fesiligia

O a ni a'afiaga e feso'ota'i ma le CAR-T Cell Therapy?

While CAR-T Cell Therapy is delivered under close supervision, it can cause cytokine release syndrome (CRS), neurological effects known as ICANS, prolonged low blood counts, low immunoglobulins and infection. Our team at Apollo Hospitals Lucknow monitors patients continuously using the ASTCT grading system and treats these effects promptly with tocilizumab, steroids and supportive care.

E fa'apefea ona ou fa'atulaga se fa'atalanoaga mo le CAR-T Cell Therapy?

You can book through the Apollo Hospitals Lucknow website, the Apollo 24|7 app, the central helpline 1860-500-1066, or in person at the registration desk. Bring or share all previous reports so the haemato-oncology team can assess suitability from the first visit.

O le a le tulaga manuia ole CAR-T Cell Therapy?

Response rates vary considerably by disease, prior treatment and tumour burden. Published trial data report high initial response rates in relapsed B-cell ALL and large B-cell lymphoma, with a proportion of patients maintaining long-term remission, but no centre can promise a cure. Your oncologist will explain the realistic expectations for your specific situation.

O le a le umi e fai ai le CAR-T Cell Therapy?

From first consultation to di